All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Generation of TKIs Challenge Standards of Care in Newly Diagnosed Ph+ ALL

March 7th 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

March 7th 2023

The FDA has approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

EU Approves Luspatercept for Anemia in Patients with Non–Transfusion-Dependent Beta Thalassemia

March 7th 2023

The European Commission has granted a full marketing authorization to luspatercept-aamt for use in adult patients with anemia associated with non–transfusion-dependent β-thalassemia.

Cabozantinib Plus Atezolizumab Misses PFS End Point in Previously Treated Advanced RCC

March 7th 2023

The combination of cabozantinib and atezolizumab did not significantly improve progression-free survival over cabozantinib alone in patients with locally advanced or metastatic clear cell or non–clear cell renal cell carcinoma who progressed during or following checkpoint inhibition, missing the primary end point of the phase 3 CONTACT-03 trial.

Lasofoxifene May Improve Vaginal/Vulvar Symptoms in Postmenopausal ER+/HER2–, ESR1-Mutated Breast Cancer

March 6th 2023

Lasofoxifene improved vaginal/vulvar symptoms compared with fulvestrant in premenopausal patients with locally advanced or metastatic estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

CEACAM5-Directed Tusamitamab Ravtansine Progresses to Phase 3 Trial in NSCLC

March 6th 2023

Clinicians tasked with treating patients with non–small cell lung cancer may soon be gaining an additional therapeutic target, this one directed at CEACAM5.

Incyte to Discontinue Phase 3 LIMBER-304 Trial of Parsaclisib Plus Ruxolitinib in Myelofibrosis

March 6th 2023

The phase 3 LIMBER-304 trial evaluating parsaclisib plus ruxolitinib in patients with myelofibrosis will be discontinued after results of a preplanned interim analysis indicated that the study is unlikely to meet its primary end point of targeted reduction in spleen volume in the intent-to-treat population.

Florida Cancer Specialists & Research Institute Names Sachin Kamath, MD Compliance Committee Chairman

March 6th 2023

Florida Cancer Specialists & Research Institute has appointed Sachin Kamath, MD as Chairman of the FCS Executive Board Compliance Committee.

FDA Approves Biosimilar Pegfilgrastim-cbqv for Febrile Neutropenia

March 6th 2023

The FDA has approved a single-dose, prefilled autoinjector presentation of pegfilgrastim-cbqv (Udenyca), which is a biosimilar of pegfilgrastim that is given the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors

March 6th 2023

The antibody-drug conjugate trastuzumab deruxtecan met the prespecified target for objective response rate and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial.

MDS Options Are Poised to Expand Across Risk Groups

March 6th 2023

Findings from several large phase 3 studies along with continued development of emerging therapies promise to alter the treatment landscape for patients with myelodysplastic syndromes.

Metronomic Chemotherapy Represents Late Treatment Option for Some Patients With Metastatic Breast Cancer

March 6th 2023

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

Real-World Outcomes With Sacituzumab Govitecan Match ASCENT in Single-Center Study

March 5th 2023

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.

Miami Breast Keynotes Highlight the Call to Action for Advocacy Efforts in Breast Cancer

March 4th 2023

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

Treatment in HR+ Early Breast Cancer May be Best Guided by Risk of Recurrence

March 4th 2023

After settling the debate of which patients with early-stage, hormone receptor–positive breast cancer require chemotherapy in addition to endocrine therapy, investigators have set their sights on determining whether ovarian function suppression can deliver the same effects of chemotherapy and when to recommend abemaciclib and olaparib.

SERMS, SERDS, and PROTEC Are Poised to Shake Up Treatments for ER+ Breast Cancer

March 4th 2023

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

Progress in Treating Brain Metastases in Breast Cancer Puts Multidisciplinary Approaches Into Focus

March 4th 2023

Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system metastases.

Artificial Intelligence, MRI, and Interdisciplinary Collaboration Topics Draw Radiologists, Surgeons to Miami

March 4th 2023

The growth of artificial intelligence allows physicians to see tumors in unprecedented ways.

I-SPY 2 Framework Could Represent the Future of Drug Development in Breast Cancer

March 3rd 2023

By moving away from adjuvant- to neoadjuvant-based protocols, such as I-SPY, investigators may be better able to develop effective treatments for patients in less time by refining the understanding of who will benefit from therapy, enabling strategies with multiple pathway targets, and testing approaches earlier in the disease course.

ADC Developments in HER2– Breast Cancer Treatment Shake Up Paradigm

March 3rd 2023

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.